MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
Boston Scientific Corporation Operating Income 2011-2026 | BSX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Boston Scientific Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.61 B | 2.6 B | 2.34 B | 1.65 B | 1.2 B | -80 M | 1.52 B | 1.51 B | 1.28 B | 447 M | -283 M | -301 M | 120 M | -3.87 B | 904 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.61 B | -3.87 B | 844 M |
Quarterly Operating Income Boston Scientific Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.05 B | 819 M | 921 M | 733 M | 520 M | 675 M | 693 M | 514 M | 552 M | - | 358 M | 423 M | 466 M | - | 387 M | 262 M | 370 M | - | -205 M | -71 M | 146 M | - | 383 M | 384 M | 541 M | - | 388 M | 392 M | 407 M | - | 377 M | 225 M | 364 M | - | 348 M | -334 M | 293 M | - | -299 M | 219 M | 24 M | - | 64 M | -69 M | 197 M | - | 103 M | 220 M | -330 M | - | -594 M | -3.59 B | 196 M | - | 174 M | 237 M | 322 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.05 B | -3.59 B | 206 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M |  USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 13.38 | 2.29 % | $ 1.81 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.28 | 1.86 % | $ 123 M |  France |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.6 | -1.96 % | $ 37.3 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 11.08 | -1.16 % | $ 314 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 25.74 | -1.0 % | $ 218 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 90.74 | -3.16 % | $ 12.3 B | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.08 | -1.89 % | $ 1.26 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 5.16 | -5.84 % | $ 1.09 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 15.14 | -4.3 % | $ 355 M | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 10.55 | -2.68 % | $ 378 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.04 | -3.7 % | $ 17.6 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 36.79 | -2.85 % | $ 1.14 B | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 61.29 | -3.34 % | $ 3.34 B |  Britain |
 |
Inspire Medical Systems
INSP
|
51 M | $ 55.11 | 0.07 % | $ 1.62 B | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.35 | 2.69 % | $ 64 M | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 84.64 | -0.83 % | $ 2.94 B | USA |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.23 | -4.3 % | $ 50 M | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 82.28 | -1.41 % | $ 48.1 B | USA |
 |
MiMedx Group
MDXG
|
63.9 M | $ 3.4 | 1.8 % | $ 502 M | USA |
 |
Nevro Corp.
NVRO
|
-126 M | - | - | $ 217 M | USA |
 |
NanoVibronix
NAOV
|
-22.9 M | - | - | $ 1.08 M | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.82 | -1.19 % | $ 34.3 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Natus Medical Incorporated
NTUS
|
23.8 M | - | 1.94 % | $ 1.05 B | USA |
 |
Orthofix Medical
OFIX
|
-81.4 M | $ 11.91 | -3.33 % | $ 472 M |  Curacao |